Anda Bularga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anda Bularga has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas Linton Mills
BHF Centre for Cardiovascular Science, University of Edinburgh, UK (N.L.M.).
12 shared publications - Andrew R. Chapman
BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom
7 shared publications - Caelan Taggart
BHF Centre of Research Excellence, University of Edinburgh, Edinburgh, United Kingdom
5 shared publications - David Ernest Newby
University of Edinburgh
5 shared publications - Dorien M. Kimenai
Usher Institute, University of Edinburgh, Edinburgh, UK
5 shared publications - Atul Anand
University of Edinburgh
4 shared publications
Latest Publications
- 1 February 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8 (1) , e250074
Diagnostic and Prognostic Performance of Pericoronary Adipose Tissue Attenuation in Suspected Acute Coronary Syndrome: Insights from the RAPID-CTCA Trial
Coronary CT angiography markers, including pericoronary adipose tissue attenuation and low-attenuation plaque burden, showed limited diagnostic and prognostic value in individuals with suspected acute coronary syndrome.
- 1 February 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8 (1) , e250074
Diagnostic and Prognostic Performance of Pericoronary Adipose Tissue Attenuation in Suspected Acute Coronary Syndrome: Insights from the RAPID-CTCA Trial
Coronary CT angiography markers, including pericoronary adipose tissue attenuation and low-attenuation plaque burden, showed limited diagnostic and prognostic value in individuals with suspected acute coronary syndrome.
- 15 October 2025
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 55 (4) , 307-313
Lessons from the Royal College of Physicians of Edinburgh’s trainee-led medical education podcasts
Medical education podcasts are increasingly popular, providing high-quality, asynchronous education to listeners. Here, we describe our experience developing the Royal College of Physicians of Edinburgh (RCPE)’s trainee-led podcasts, Clinical Conversations and Career Conversations . Both podcasts have been designed by resident doctors for resident doctors and are in high demand, approaching one-quarter of a million plays and international listenership. In this article, we explore the myriad benefits for resident doctor hosts, guest speakers and staff involved in podcast production, as well as reflecting on the challenges faced. Providing free, high-quality medical education is a core purpose of RCPE to benefit patients, physicians and healthcare systems around the world, and podcasts play a key role in this. By openly sharing our achievements, challenges and lessons learnt during our journey, we hope we may inspire others to engage in creating high-quality, accessible medical education.
- 15 October 2025
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 55 (4) , 307-313
Lessons from the Royal College of Physicians of Edinburgh’s trainee-led medical education podcasts
Medical education podcasts are increasingly popular, providing high-quality, asynchronous education to listeners. Here, we describe our experience developing the Royal College of Physicians of Edinburgh (RCPE)’s trainee-led podcasts, Clinical Conversations and Career Conversations . Both podcasts have been designed by resident doctors for resident doctors and are in high demand, approaching one-quarter of a million plays and international listenership. In this article, we explore the myriad benefits for resident doctor hosts, guest speakers and staff involved in podcast production, as well as reflecting on the challenges faced. Providing free, high-quality medical education is a core purpose of RCPE to benefit patients, physicians and healthcare systems around the world, and podcasts play a key role in this. By openly sharing our achievements, challenges and lessons learnt during our journey, we hope we may inspire others to engage in creating high-quality, accessible medical education.
- Open Access
- 4 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (8) , 1421-1430
The assessment and management of patients with type 2 myocardial infarction: an international Delphi study
Aims: Type 2 myocardial infarction due to myocardial oxygen supply–demand imbalance is associated with poor outcomes. There are no guidelines to inform care for these patients. The consensus on the assessment and management of type 2 myocardial infarction is gained. Methods and results: An international e-Delphi study including experts in type 2 myocardial infarction identified through systematic review was conducted. Participants were asked to describe their approach to (i) definition and diagnosis, (ii) risk stratification, (iii) assessment of coronary artery disease and cardiac function, (iv) specialty management, (v) treatment and secondary prevention, and (vi) communication and rehabilitation. Statements generated in round one were circulated, with consensus defined a priori as ≥70% agreement on a 5-point Likert scale. Where no consensus was reached, statements were amended and recirculated for a final round. The response rate was 56% (38/68), 54% (37/68), and 72% (49/68) in the first, second, and third rounds, respectively. Following the first round, 67 unique statements were generated across six domains. Overall, consensus was achieved on 64% (43/67) of statements. Consensus was achieved for 42% (5/12) of statements on the diagnosis of type 2 myocardial infarction, 75% (3/4) on risk stratification, 50% (9/18) on the assessment of coronary artery disease and cardiac function, 60% (6/10), on specialty management, 100% (9/9) on treatment and secondary prevention, and 79% (11/15) on communication and rehabilitation. Conclusion: Consensus was obtained across a number of domains for the assessment and management of patients with type 2 myocardial infarction. However, there was limited agreement amongst experts on the diagnostic criteria, which may benefit from refinement.
- 4 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (8) , 1421-1430
Open AccessThe assessment and management of patients with type 2 myocardial infarction: an international Delphi study
Aims: Type 2 myocardial infarction due to myocardial oxygen supply–demand imbalance is associated with poor outcomes. There are no guidelines to inform care for these patients. The consensus on the assessment and management of type 2 myocardial infarction is gained. Methods and results: An international e-Delphi study including experts in type 2 myocardial infarction identified through systematic review was conducted. Participants were asked to describe their approach to (i) definition and diagnosis, (ii) risk stratification, (iii) assessment of coronary artery disease and cardiac function, (iv) specialty management, (v) treatment and secondary prevention, and (vi) communication and rehabilitation. Statements generated in round one were circulated, with consensus defined a priori as ≥70% agreement on a 5-point Likert scale. Where no consensus was reached, statements were amended and recirculated for a final round. The response rate was 56% (38/68), 54% (37/68), and 72% (49/68) in the first, second, and third rounds, respectively. Following the first round, 67 unique statements were generated across six domains. Overall, consensus was achieved on 64% (43/67) of statements. Consensus was achieved for 42% (5/12) of statements on the diagnosis of type 2 myocardial infarction, 75% (3/4) on risk stratification, 50% (9/18) on the assessment of coronary artery disease and cardiac function, 60% (6/10), on specialty management, 100% (9/9) on treatment and secondary prevention, and 79% (11/15) on communication and rehabilitation. Conclusion: Consensus was obtained across a number of domains for the assessment and management of patients with type 2 myocardial infarction. However, there was limited agreement amongst experts on the diagnostic criteria, which may benefit from refinement.
- Open Access
- 23 June 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (30) , 2846-2858
Troponin in early presenters to rule out myocardial infarction
Aims: Whether a single cardiac troponin measurement can safely rule out myocardial infarction in patients presenting within a few hours of symptom onset is uncertain. The study aim was to assess the performance of troponin in early presenters. Methods and results: In patients with possible myocardial infarction, the diagnostic performance of a single measurement of high-sensitivity cardiac troponin I at presentation was evaluated and externally validated in those tested ≤3, 4–12, and >12 h from symptom onset. The limit-of-detection (2 ng/L), rule-out (5 ng/L), and sex-specific 99th centile (16 ng/L in women; 34 ng/L in men) thresholds were compared. In 41 103 consecutive patients [60 (17) years, 46% women], 12 595 (31%) presented within 3 h, and 3728 (9%) had myocardial infarction. In those presenting ≤3 h, a threshold of 2 ng/L had greater sensitivity and negative predictive value [99.4% (95% confidence interval 99.2%–99.5%) and 99.7% (99.6%–99.8%)] compared with 5 ng/L [96.5% (96.2%–96.8%) and 99.3% (99.1%–99.4%)]. In those presenting ≥3 h, the sensitivity and negative predictive value were similar for both thresholds. The sensitivity of the 99th centile was low in early and late presenters at 71.4% (70.6%–72.2%) and 92.5% (92.0%–93.0%), respectively. Findings were consistent in an external validation cohort of 7088 patients. Conclusion: In early presenters, a single measurement of high-sensitivity cardiac troponin I below the limit of detection may facilitate the safe rule out of myocardial infarction. The 99th centile should not be used to rule out myocardial infarction at presentation even in those presenting later following symptom onset.
- 23 June 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (30) , 2846-2858
Open AccessTroponin in early presenters to rule out myocardial infarction
Aims: Whether a single cardiac troponin measurement can safely rule out myocardial infarction in patients presenting within a few hours of symptom onset is uncertain. The study aim was to assess the performance of troponin in early presenters. Methods and results: In patients with possible myocardial infarction, the diagnostic performance of a single measurement of high-sensitivity cardiac troponin I at presentation was evaluated and externally validated in those tested ≤3, 4–12, and >12 h from symptom onset. The limit-of-detection (2 ng/L), rule-out (5 ng/L), and sex-specific 99th centile (16 ng/L in women; 34 ng/L in men) thresholds were compared. In 41 103 consecutive patients [60 (17) years, 46% women], 12 595 (31%) presented within 3 h, and 3728 (9%) had myocardial infarction. In those presenting ≤3 h, a threshold of 2 ng/L had greater sensitivity and negative predictive value [99.4% (95% confidence interval 99.2%–99.5%) and 99.7% (99.6%–99.8%)] compared with 5 ng/L [96.5% (96.2%–96.8%) and 99.3% (99.1%–99.4%)]. In those presenting ≥3 h, the sensitivity and negative predictive value were similar for both thresholds. The sensitivity of the 99th centile was low in early and late presenters at 71.4% (70.6%–72.2%) and 92.5% (92.0%–93.0%), respectively. Findings were consistent in an external validation cohort of 7088 patients. Conclusion: In early presenters, a single measurement of high-sensitivity cardiac troponin I below the limit of detection may facilitate the safe rule out of myocardial infarction. The 99th centile should not be used to rule out myocardial infarction at presentation even in those presenting later following symptom onset.
- Open Access
- 31 January 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (5) , 447-449
Impact of Patient Selection on Performance of an Early Rule-Out Pathway for Myocardial Infarction: From Research to the Real World
- 31 January 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (5) , 447-449
Open AccessImpact of Patient Selection on Performance of an Early Rule-Out Pathway for Myocardial Infarction: From Research to the Real World
- 27 October 2022
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 4 (5) , e220081
Distinguishing Type 1 from Type 2 Myocardial Infarction by Using CT Coronary Angiography
There may be important differences in the plaque composition of patients with type 1 and type 2 myocardial infarction, which can be quantified at CT coronary angiography. Purpose To determine whether quantitative plaque characterization by using CT coronary angiography (CTCA) can discriminate between type 1 and type 2 myocardial infarction. Materials and Methods Thi...
- 27 October 2022
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 4 (5) , e220081
Distinguishing Type 1 from Type 2 Myocardial Infarction by Using CT Coronary Angiography
There may be important differences in the plaque composition of patients with type 1 and type 2 myocardial infarction, which can be quantified at CT coronary angiography. Purpose To determine whether quantitative plaque characterization by using CT coronary angiography (CTCA) can discriminate between type 1 and type 2 myocardial infarction. Materials and Methods Thi...
- Open Access
- 27 July 2022
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (8) , 1015-1019
Macrotroponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection
Patient 1 was a 28-year-old Caucasian woman who presented with a 4-day history of chest pain to the same day emergency care unit at the Western General Hospital, Edinburgh, Scotland. The patient had received a second dose of the mRNA-1273 (Moderna) vaccine for COVID-19 five days previously. After vaccination, she felt unwell with fever and dry cough. Shortly after, she developed chest pain. The patient had no background medical history and her clinical examination was unremarkable.
- 27 July 2022
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (8) , 1015-1019
Open AccessMacrotroponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection
Patient 1 was a 28-year-old Caucasian woman who presented with a 4-day history of chest pain to the same day emergency care unit at the Western General Hospital, Edinburgh, Scotland. The patient had received a second dose of the mRNA-1273 (Moderna) vaccine for COVID-19 five days previously. After vaccination, she felt unwell with fever and dry cough. Shortly after, she developed chest pain. The patient had no background medical history and her clinical examination was unremarkable.
- Open Access
- 19 April 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 145 (16) , 1188-1200
Coronary Artery and Cardiac Disease in Patients With Type 2 Myocardial Infarction: A Prospective Cohort Study
Background: Type 2 myocardial infarction is caused by myocardial oxygen supply-demand imbalance, and its diagnosis is increasingly common with the advent of high-sensitivity cardiac troponin assays. Although this diagnosis is associated with poor outcomes, widespread uncertainty and confusion remain among clinicians as to how to investigate and manage this heterogeneous group of patients with type 2 myocardial infarction. Methods: In a prospective cohort study, 8064 consecutive patients with increased cardiac troponin concentrations were screened to identify patients with type 2 myocardial infarction. We excluded patients with frailty or renal or hepatic failure. All study participants underwent coronary (invasive or computed tomography angiography) and cardiac (magnetic resonance or echocardiography) imaging, and the underlying causes of infarction were independently adjudicated. The primary outcome was the prevalence of coronary artery disease. Results: In 100 patients with a provisional diagnosis of type 2 myocardial infarction (median age, 65 years [interquartile range, 55–74 years]; 43% women), coronary and cardiac imaging reclassified the diagnosis in 7 patients: type 1 or 4b myocardial infarction in 5 and acute myocardial injury in 2 patients. In those with type 2 myocardial infarction, median cardiac troponin I concentrations were 195 ng/L (interquartile range, 62–760 ng/L) at presentation and 1165 ng/L (interquartile range, 277–3782 ng/L) on repeat testing. The prevalence of coronary artery disease was 68% (63 of 93), which was obstructive in 30% (28 of 93). Infarct-pattern late gadolinium enhancement or regional wall motion abnormalities were observed in 42% (39 of 93), and left ventricular systolic dysfunction was seen in 34% (32 of 93). Only 10 patients had both normal coronary and normal cardiac imaging. Coronary artery disease and left ventricular systolic dysfunction were previously unrecognized in 60% (38 of 63) and 84% (27 of 32), respectively, with only 33% (21 of 63) and 19% (6 of 32) on evidence-based treatments. Conclusions: Systematic coronary and cardiac imaging of patients with type 2 myocardial infarction identified coronary artery disease in two-thirds and left ventricular systolic dysfunction in one-third of patients. Unrecognized and untreated coronary or cardiac disease is seen in most patients with type 2 myocardial infarction, presenting opportunities for initiation of evidence-based treatments with major potential to improve clinical outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03338504.
- 19 April 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 145 (16) , 1188-1200
Open AccessCoronary Artery and Cardiac Disease in Patients With Type 2 Myocardial Infarction: A Prospective Cohort Study
Background: Type 2 myocardial infarction is caused by myocardial oxygen supply-demand imbalance, and its diagnosis is increasingly common with the advent of high-sensitivity cardiac troponin assays. Although this diagnosis is associated with poor outcomes, widespread uncertainty and confusion remain among clinicians as to how to investigate and manage this heterogeneous group of patients with type 2 myocardial infarction. Methods: In a prospective cohort study, 8064 consecutive patients with increased cardiac troponin concentrations were screened to identify patients with type 2 myocardial infarction. We excluded patients with frailty or renal or hepatic failure. All study participants underwent coronary (invasive or computed tomography angiography) and cardiac (magnetic resonance or echocardiography) imaging, and the underlying causes of infarction were independently adjudicated. The primary outcome was the prevalence of coronary artery disease. Results: In 100 patients with a provisional diagnosis of type 2 myocardial infarction (median age, 65 years [interquartile range, 55–74 years]; 43% women), coronary and cardiac imaging reclassified the diagnosis in 7 patients: type 1 or 4b myocardial infarction in 5 and acute myocardial injury in 2 patients. In those with type 2 myocardial infarction, median cardiac troponin I concentrations were 195 ng/L (interquartile range, 62–760 ng/L) at presentation and 1165 ng/L (interquartile range, 277–3782 ng/L) on repeat testing. The prevalence of coronary artery disease was 68% (63 of 93), which was obstructive in 30% (28 of 93). Infarct-pattern late gadolinium enhancement or regional wall motion abnormalities were observed in 42% (39 of 93), and left ventricular systolic dysfunction was seen in 34% (32 of 93). Only 10 patients had both normal coronary and normal cardiac imaging. Coronary artery disease and left ventricular systolic dysfunction were previously unrecognized in 60% (38 of 63) and 84% (27 of 32), respectively, with only 33% (21 of 63) and 19% (6 of 32) on evidence-based treatments. Conclusions: Systematic coronary and cardiac imaging of patients with type 2 myocardial infarction identified coronary artery disease in two-thirds and left ventricular systolic dysfunction in one-third of patients. Unrecognized and untreated coronary or cardiac disease is seen in most patients with type 2 myocardial infarction, presenting opportunities for initiation of evidence-based treatments with major potential to improve clinical outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03338504.
- Open Access
- 25 August 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (2) , 127-135
Risk factors for type 1 and type 2 myocardial infarction
Whilst the risk factors for type 1 myocardial infarction due to atherosclerotic plaque rupture and thrombosis are established, our understanding of the factors that predispose to type 2 myocardial infarction during acute illness is still emerging. Our aim was to evaluate and compare the risk factors for type 1 and type 2 myocardial infarction. We conducted a secondary analysis of a multi-centre randomized trial population of 48 282 consecutive patients attending hospital with suspected acute coronary syndrome. The diagnosis of myocardial infarction during the index presentation and all subsequent reattendances was adjudicated according to the Universal Definition of Myocardial Infarction. Cox regression was used to identify predictors of future type 1 and type 2 myocardial infarction during a 1-year follow-up period. Within 1 year, 1331 patients had a subsequent myocardial infarction, with 924 and 407 adjudicated as type 1 and type 2 myocardial infarction, respectively. Risk factors for type 1 and type 2 myocardial infarction were similar, with age, hyperlipidaemia, diabetes, abnormal renal function, and known coronary disease predictors for both (P < 0.05 for all). Whilst women accounted for a greater proportion of patients with type 2 as compared to type 1 myocardial infarction, after adjustment for other risk factors, sex was not a predictor of type 2 myocardial events [adjusted hazard ratio (aHR) 0.82, 95% confidence interval (CI) 0.66–1.01]. The strongest predictor of type 2 myocardial infarction was a prior history of type 2 events (aHR 6.18, 95% CI 4.70–8.12). Risk factors for coronary disease that are associated with type 1 myocardial infarction are also important predictors of type 2 events during acute illness. Treatment of these risk factors may reduce future risk of both type 1 and type 2 myocardial infarction. Determining vulnerability to future type 2 myocardial infarction events. The role of illness severity, risk factors for cardiovascular disease, and presence of coronary artery disease in those with type 2 myocardial infarction.
- 25 August 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (2) , 127-135
Open AccessRisk factors for type 1 and type 2 myocardial infarction
Whilst the risk factors for type 1 myocardial infarction due to atherosclerotic plaque rupture and thrombosis are established, our understanding of the factors that predispose to type 2 myocardial infarction during acute illness is still emerging. Our aim was to evaluate and compare the risk factors for type 1 and type 2 myocardial infarction. We conducted a secondary analysis of a multi-centre randomized trial population of 48 282 consecutive patients attending hospital with suspected acute coronary syndrome. The diagnosis of myocardial infarction during the index presentation and all subsequent reattendances was adjudicated according to the Universal Definition of Myocardial Infarction. Cox regression was used to identify predictors of future type 1 and type 2 myocardial infarction during a 1-year follow-up period. Within 1 year, 1331 patients had a subsequent myocardial infarction, with 924 and 407 adjudicated as type 1 and type 2 myocardial infarction, respectively. Risk factors for type 1 and type 2 myocardial infarction were similar, with age, hyperlipidaemia, diabetes, abnormal renal function, and known coronary disease predictors for both (P < 0.05 for all). Whilst women accounted for a greater proportion of patients with type 2 as compared to type 1 myocardial infarction, after adjustment for other risk factors, sex was not a predictor of type 2 myocardial events [adjusted hazard ratio (aHR) 0.82, 95% confidence interval (CI) 0.66–1.01]. The strongest predictor of type 2 myocardial infarction was a prior history of type 2 events (aHR 6.18, 95% CI 4.70–8.12). Risk factors for coronary disease that are associated with type 1 myocardial infarction are also important predictors of type 2 events during acute illness. Treatment of these risk factors may reduce future risk of both type 1 and type 2 myocardial infarction. Determining vulnerability to future type 2 myocardial infarction events. The role of illness severity, risk factors for cardiovascular disease, and presence of coronary artery disease in those with type 2 myocardial infarction.
- Open Access
- 17 August 2021
- Published by Wolters Kluwer Health in Circulation
- Vol. 144 (7) , 528-538
Cardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction
Background: Although the 99th percentile is the recommended diagnostic threshold for myocardial infarction, some guidelines also advocate the use of higher troponin thresholds to rule in myocardial infarction at presentation. It is unclear whether the magnitude or change in troponin concentration can differentiate causes of myocardial injury and infarction in practice. Methods: In a secondary analysis of a multicenter randomized controlled trial, we identified 46 092 consecutive patients presenting with suspected acute coronary syndrome without ST-segment–elevation myocardial infarction. High-sensitivity cardiac troponin I concentrations at presentation and on serial testing were compared between patients with myocardial injury and infarction. The positive predictive value and specificity were determined at the sex-specific 99th percentile upper reference limit and rule-in thresholds of 64 ng/L and 5-fold of the upper reference limit for a diagnosis of type 1 myocardial infarction. Results: Troponin was above the 99th percentile in 8188 patients (18%). The diagnosis was type 1 or type 2 myocardial infarction in 50% and 14% and acute or chronic myocardial injury in 20% and 16%, respectively. Troponin concentrations were similar at presentation in type 1 (median [25th–75th percentile] 91 [30–493] ng/L) and type 2 (50 [22–147] ng/L) myocardial infarction and in acute (50 [26–134] ng/L) and chronic (51 [31–130] ng/L) myocardial injury. The 99th percentile and rule-in thresholds of 64 ng/L and 5-fold upper reference limit gave a positive predictive value of 57% (95% CI, 56%–58%), 59% (58%–61%), and 62% (60%–64%) and a specificity of 96% (96%–96%), 96% (96%–96%), and 98% (97%–98%), respectively. The absolute, relative, and rate of change in troponin concentration were highest in patients with type 1 myocardial infarction ( P <0.001 for all). Discrimination improved when troponin concentration and change in troponin were combined compared with troponin concentration at presentation alone (area under the curve, 0.661 [0.642–0.680] versus 0.613 [0.594–0.633]). Conclusions: Although we observed important differences in the kinetics, cardiac troponin concentrations at presentation are insufficient to distinguish type 1 myocardial infarction from other causes of myocardial injury or infarction in practice and should not guide management decisions in isolation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01852123.
- 17 August 2021
- Published by Wolters Kluwer Health in Circulation
- Vol. 144 (7) , 528-538
Open AccessCardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction
Background: Although the 99th percentile is the recommended diagnostic threshold for myocardial infarction, some guidelines also advocate the use of higher troponin thresholds to rule in myocardial infarction at presentation. It is unclear whether the magnitude or change in troponin concentration can differentiate causes of myocardial injury and infarction in practice. Methods: In a secondary analysis of a multicenter randomized controlled trial, we identified 46 092 consecutive patients presenting with suspected acute coronary syndrome without ST-segment–elevation myocardial infarction. High-sensitivity cardiac troponin I concentrations at presentation and on serial testing were compared between patients with myocardial injury and infarction. The positive predictive value and specificity were determined at the sex-specific 99th percentile upper reference limit and rule-in thresholds of 64 ng/L and 5-fold of the upper reference limit for a diagnosis of type 1 myocardial infarction. Results: Troponin was above the 99th percentile in 8188 patients (18%). The diagnosis was type 1 or type 2 myocardial infarction in 50% and 14% and acute or chronic myocardial injury in 20% and 16%, respectively. Troponin concentrations were similar at presentation in type 1 (median [25th–75th percentile] 91 [30–493] ng/L) and type 2 (50 [22–147] ng/L) myocardial infarction and in acute (50 [26–134] ng/L) and chronic (51 [31–130] ng/L) myocardial injury. The 99th percentile and rule-in thresholds of 64 ng/L and 5-fold upper reference limit gave a positive predictive value of 57% (95% CI, 56%–58%), 59% (58%–61%), and 62% (60%–64%) and a specificity of 96% (96%–96%), 96% (96%–96%), and 98% (97%–98%), respectively. The absolute, relative, and rate of change in troponin concentration were highest in patients with type 1 myocardial infarction ( P <0.001 for all). Discrimination improved when troponin concentration and change in troponin were combined compared with troponin concentration at presentation alone (area under the curve, 0.661 [0.642–0.680] versus 0.613 [0.594–0.633]). Conclusions: Although we observed important differences in the kinetics, cardiac troponin concentrations at presentation are insufficient to distinguish type 1 myocardial infarction from other causes of myocardial injury or infarction in practice and should not guide management decisions in isolation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01852123.